Linda Marban – VJRegenMed

Cardiosphere-derived cells in myocardial regeneration

admin_vjr_user — Fri, 13 Aug 2021 12:05:07 +0000

Linda Marban, PhD, Capricor Therapeutics, Beverly Hills, CA, introduces CAP-1002, an allogeneic cardiosphere-derived cell (CDC) therapy that promotes the regeneration of cardiac muscle by stimulating the release of exosomes, thus inducing endogenous repair mechanisms, a reduction in inflammation and ultimately, muscle tissue generation. Clinical trial data indicates that CAP-1002 therapy can result in significant improvements in cardiac and skeletal muscle in patients with Duchenne muscular dystrophy (DMD). CDC-derived extracellular vesicles (EVs) are also being investigated as a therapeutic given their tropism to cardiac and skeletal muscle and ease of storage and delivery. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.

Exosomes: a game changer in mRNA-based therapeutics?

admin_vjr_user — Fri, 21 May 2021 17:21:49 +0000

Linda Marban, PhD, Capricor Therapeutics, Beverly Hills, CA, describes excitement around the use of exosomes as a drug delivery vehicle and the potential this technology holds for the development of mRNA-based therapeutics in the future. Membrane-bound exosomes can be easily directed to the site of injury and enter the cell to drive protein expression, making them useful tools for the delivery of biological contents and could replace lipid nanoparticles for such applications in the future. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.

Exosome-based mRNA vaccines against SARS-CoV-2

admin_vjr_user — Fri, 21 May 2021 17:21:45 +0000

Linda Marban, PhD, Capricor Therapeutics, Beverly Hills, CA, describes ongoing research into a novel exosome-mediated, multivalent mRNA vaccine against SARS-CoV-2. While lipid nanoparticles have been used as drug delivery vehicles in other SARS-CoV-2 vaccines, the use of exosomes could reduce toxicity, enhance the immune response and potentially allow repeat vaccine delivery, which may be necessary in the form of vaccine boosters. The use of a multivalent approach, incorporating both a spike and nucleocapsid protein into the vaccine candidate, could also help protect against more pathogenic SARS-CoV-2 variants in the future. This interview took place during the American Society for Cell & Gene Therapy 24th Annual Meeting 2021.